Document is current
Any future updates will be listed below
-
Authors
Jayne, David https://orcid.org/0000-0002-1712-0637
Rovin, Brad https://orcid.org/0000-0001-5639-0210
Mysler, Eduardo https://orcid.org/0000-0002-8993-0313
Furie, Richard https://orcid.org/0000-0001-6712-1585
Houssiau, Frédéric https://orcid.org/0000-0003-1451-083X
Trasieva, Teodora
Knagenhjelm, Jacob
Schwetje, Erik
Tang, Weifeng
Tummala, Raj
Lindholm, Catharina
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02547922 at ClinicalTrials.govnct02547922 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1292
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
https://doi.org/10.1136/annrheumdis-2021-221478
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1605
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1569
POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
https://doi.org/10.1136/annrheumdis-2022-eular.1654
PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.122
Collagen Remodeling Biomarkers in Lupus Nephritis
https://doi.org/10.34067/kid.0004732021
nct05138133 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1292
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
https://doi.org/10.1136/annrheumdis-2021-221478
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1605
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1569
POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
https://doi.org/10.1136/annrheumdis-2022-eular.1654
PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.122
Collagen Remodeling Biomarkers in Lupus Nephritis
https://doi.org/10.34067/kid.0004732021
nct02547922 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
Advances in the management of chronic kidney disease
https://doi.org/10.1136/bmj-2022-074216
nct02547922 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1292
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
https://doi.org/10.1136/annrheumdis-2021-221478
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1605
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1569
POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
https://doi.org/10.1136/annrheumdis-2022-eular.1654
PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.122
Collagen Remodeling Biomarkers in Lupus Nephritis
https://doi.org/10.34067/kid.0004732021
nct05138133 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1292
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
https://doi.org/10.1136/annrheumdis-2021-221478
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1605
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1569
POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
https://doi.org/10.1136/annrheumdis-2022-eular.1654
PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.122
Collagen Remodeling Biomarkers in Lupus Nephritis
https://doi.org/10.34067/kid.0004732021
nct05138133 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
Advances in the management of chronic kidney disease
https://doi.org/10.1136/bmj-2022-074216
nct02446912 at ClinicalTrials.govDocuments that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
Advances in the management of chronic kidney disease
https://doi.org/10.1136/bmj-2022-074216
nct02446899 at ClinicalTrials.govDocuments that mention this clinical trial
OP0131 ANIFROLUMAB EFFECTS ON RASH AND ARTHRITIS IN PATIENTS WITH SLE AND IMPACT OF INTERFERON SIGNAL IN POOLED DATA FROM PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.1471
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
https://doi.org/10.1136/lupus-2024-el.31
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
https://doi.org/10.1136/ard-2022-222748
Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data
https://doi.org/10.1136/lupus-2025-001916
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
https://doi.org/10.1136/lupus-2017-000252
POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
https://doi.org/10.1136/annrheumdis-2022-eular.1654
POS0709 SUSTAINED BICLA AND BILAG ORGAN DOMAIN RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING ANIFROLUMAB IN TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.897
POS0708 EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PREINFUSION PROPHYLACTIC TREATMENT IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2022-eular.896
POS0688 CHARACTERIZATION OF PK/PD OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SLE
https://doi.org/10.1136/annrheumdis-2021-eular.1464
P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials
https://doi.org/10.1136/lupus-2024-el.121
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
https://doi.org/10.1136/lupus-2022-000761
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
https://doi.org/10.1136/annrheumdis-2021-221425
Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature
https://doi.org/10.1136/bmjopen-2019-036563
POS0691 EFFECTS OF ANIFROLUMAB ON RENAL DISEASE IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2021-eular.1618
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
https://doi.org/10.1136/annrheumdis-2017-eular.3719
POS0733 VALIDATION OF THE SLE-DAS RESPONDER INDEX AS AN ACCURATE AND FEASIBLE ENDPOINT FOR SLE CLINICAL TRIALS: A POST-HOC STUDY IN THE PHASE 2 AND 3 ANIFROLUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4639
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials
https://doi.org/10.1136/ard-2023-225445
Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials
https://doi.org/10.1136/lupus-2025-001891
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
https://doi.org/10.1136/lupus-2020-000464
1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab
https://doi.org/10.1136/lupus-2023-lupus21century.99
AB0514 LABORATORY MARKER IMPROVEMENTS FOLLOWING LONG-TERM TREATMENT WITH ANIFROLUMAB IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE PLACEBO-CONTROLLED TULIP EXTENSION STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.1534
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
https://doi.org/10.1136/annrheumdis-2021-221847
P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
https://doi.org/10.1136/lupus-2024-el.181
POS0683 NOVEL STRINGENT OUTCOME MEASURES APPLIED TO THE PHASE 2 AND 3 ANIFROLUMAB TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.702
POS0541 GLUCOCORTICOID REDUCTION AND WITHDRAWAL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS RECEIVING LONG-TERM ANIFROLUMAB TREATMENT
https://doi.org/10.1136/annrheumdis-2024-eular.1401
OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.1568
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
AB0425 WHAT DOES IT MEAN TO BE A DUAL BICLA AND SRI(4) RESPONDER? A POOLED ANALYSIS OF TWO PHASE 3 TRIALS IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2022-eular.900
POS0367 IMPROVEMENT OF INDIVIDUAL MUCOCUTANEOUS MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB
https://doi.org/10.1136/annrheumdis-2022-eular.690
POS0684 RELATIONSHIP OF ANIFROLUMAB PK WITH EFFICACY AND SAFETY IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2021-eular.803
AB0993 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT WITH ANIFROLUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND LYMPHOPENIA
https://doi.org/10.1136/annrheumdis-2024-eular.1377
POS0024 IMPROVEMENT OF HEMATOLOGICAL PARAMETERS DURING LONG-TERM ANIFROLUMAB TREATMENT AND ASSOCIATION WITH WEEK 52 BICLA RESPONSE
https://doi.org/10.1136/annrheumdis-2024-eular.2627
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies
https://doi.org/10.1136/lupus-2025-001499
nct02547922 at ClinicalTrials.govDocuments that mention this clinical trial
OP0131 ANIFROLUMAB EFFECTS ON RASH AND ARTHRITIS IN PATIENTS WITH SLE AND IMPACT OF INTERFERON SIGNAL IN POOLED DATA FROM PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.1471
O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
https://doi.org/10.1136/lupus-2024-el.31
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
https://doi.org/10.1136/ard-2022-222748
Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data
https://doi.org/10.1136/lupus-2025-001916
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
https://doi.org/10.1136/lupus-2017-000252
POS0709 SUSTAINED BICLA AND BILAG ORGAN DOMAIN RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING ANIFROLUMAB IN TWO PHASE 3 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.897
POS0708 EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PREINFUSION PROPHYLACTIC TREATMENT IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2022-eular.896
POS0688 CHARACTERIZATION OF PK/PD OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SLE
https://doi.org/10.1136/annrheumdis-2021-eular.1464
1401 Effects of anifrolumab on renal disease in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2021-lupus21century.78
P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials
https://doi.org/10.1136/lupus-2024-el.121
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
https://doi.org/10.1136/lupus-2022-000761
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
https://doi.org/10.1136/annrheumdis-2021-221425
Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature
https://doi.org/10.1136/bmjopen-2019-036563
POS0691 EFFECTS OF ANIFROLUMAB ON RENAL DISEASE IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2021-eular.1618
OP0301 Type i ifn gene signature test–high and –low patients with moderate to severe sle disease activity have distinct gene expression signatures of immunologic pathways and cell types
https://doi.org/10.1136/annrheumdis-2017-eular.3719
POS0733 VALIDATION OF THE SLE-DAS RESPONDER INDEX AS AN ACCURATE AND FEASIBLE ENDPOINT FOR SLE CLINICAL TRIALS: A POST-HOC STUDY IN THE PHASE 2 AND 3 ANIFROLUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.4639
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials
https://doi.org/10.1136/ard-2023-225445
Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials
https://doi.org/10.1136/lupus-2025-001891
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
https://doi.org/10.1136/lupus-2020-000464
1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab
https://doi.org/10.1136/lupus-2023-lupus21century.99
AB0514 LABORATORY MARKER IMPROVEMENTS FOLLOWING LONG-TERM TREATMENT WITH ANIFROLUMAB IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE PLACEBO-CONTROLLED TULIP EXTENSION STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.1534
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
https://doi.org/10.1136/annrheumdis-2021-221847
P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
https://doi.org/10.1136/lupus-2024-el.181
POS0683 NOVEL STRINGENT OUTCOME MEASURES APPLIED TO THE PHASE 2 AND 3 ANIFROLUMAB TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.702
POS0541 GLUCOCORTICOID REDUCTION AND WITHDRAWAL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS RECEIVING LONG-TERM ANIFROLUMAB TREATMENT
https://doi.org/10.1136/annrheumdis-2024-eular.1401
OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.1568
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
https://doi.org/10.1136/lupus-2023-000907
AB0425 WHAT DOES IT MEAN TO BE A DUAL BICLA AND SRI(4) RESPONDER? A POOLED ANALYSIS OF TWO PHASE 3 TRIALS IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2022-eular.900
POS0367 IMPROVEMENT OF INDIVIDUAL MUCOCUTANEOUS MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB
https://doi.org/10.1136/annrheumdis-2022-eular.690
POS0684 RELATIONSHIP OF ANIFROLUMAB PK WITH EFFICACY AND SAFETY IN PATIENTS WITH SLE
https://doi.org/10.1136/annrheumdis-2021-eular.803
AB0993 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT WITH ANIFROLUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND LYMPHOPENIA
https://doi.org/10.1136/annrheumdis-2024-eular.1377
POS0024 IMPROVEMENT OF HEMATOLOGICAL PARAMETERS DURING LONG-TERM ANIFROLUMAB TREATMENT AND ASSOCIATION WITH WEEK 52 BICLA RESPONSE
https://doi.org/10.1136/annrheumdis-2024-eular.2627
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies
https://doi.org/10.1136/lupus-2025-001499
Documents that mention this clinical trial
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial
https://doi.org/10.1136/rmdopen-2025-005932
POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1292
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
https://doi.org/10.1136/annrheumdis-2021-221478
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1605
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
https://doi.org/10.1136/lupus-2023-000910
OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1569
POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
https://doi.org/10.1136/annrheumdis-2022-eular.1654
PO.5.97 The renal activity index for lupus (RAIL) identifies active renal disease in SLE patients and its longitudinal score associates with renal responses in lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.122
Collagen Remodeling Biomarkers in Lupus Nephritis
https://doi.org/10.34067/kid.0004732021
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
